LeonaBio, Inc. Deferred Tax Assets, Valuation Allowance
LeonaBio, Inc. (LONA) had Deferred Tax Assets, Valuation Allowance of $112.62 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $112.62M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $91.95M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $71.25M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $42.98M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $112.62M 10-K · filed 2026-03-31 |
| 2024-12-31 | $91.95M 10-K · filed 2026-03-31 |
| 2023-12-31 | $71.25M 10-K · filed 2025-02-27 |
| 2022-12-31 | $42.98M 10-K · filed 2024-02-22 |
| 2021-12-31 | $22.57M 10-K · filed 2023-03-23 |
| 2020-12-31 | $9.10M 10-K · filed 2022-03-28 |
| 2019-12-31 | $4.79M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |